Mucosis Appoints Thomas Johnston As Chief Business Officer
Mucosis B.V. announced the appointment of Thomas Johnston as Chief Business Officer. In this role he will have global responsibility for the licensing and marketing of Mucosis’s technologies, negotiating corporate partnerships and other strategic alliances.
Mr. Johnston joins Mucosis from Novavax Inc, a Nasdaq-listed clinical-stage biopharmaceutical company. As Vice President of Strategy he developed and executed a regional partnership strategy with deals in India, Mexico, and South Korea. Prior to Novavax, Mr. Johnston served as an executive-level strategic consultant in a number of industries including biotech, and held various senior-level positions with a number of world-class organizations such as Comcast, Microsoft, and Schlumberger. Mr. Johnston holds an M.B.A. from The Wharton Business School and a Bachelor of Science degree in Computer Science from Arcadia University.
Organizations
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Positive Preclinical Data with Transition Therapeutics Alzheimer's Disease Drug Candidate AZD-103
ImmunoVaccine Technologies Inc. to Acquire Immunotope Inc.
Helix announces election of new board member
Miroslav Radman wins the 2011 FEMS-Lwoff Award.
HIV-derived antibacterial shows promise against drug-resistant bacteria
Eisai Receives Approval for a New Oral Jelly Formulation of Aricept for the Treatment of Alzheimer’s Disease in Japan
Zelluna Immunotherapy appoints Miguel Forte as Chief Executive Officer - Appointment to drive Zelluna through next stage of international clinical-phase development
Pepscan Therapeutics establishes a Research Collaboration with Tibotec Pharmaceuticals
Sigma-Aldrich and Sangamo BioSciences Announce Alliance to Develop Zinc Finger-Based Laboratory Research Reagents
Cardio3 BioSciences Receives ISO-13485 Certification
Gene Logic Expands International Operations - Establishes Staff in UK and Germany - Forms Gene Logic K.K. to Serve Japanese Market
